A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria

• •Patients who have a life expectancy of at least 12 weeks
• •Patients with advanced HCC (unresectable, and/or metastatic) which has been histologically or cytologically documented
• •Patients must have at least one tumor lesion that meets both of the following criteria:
• •* can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)
• •* has not been previously treated with local therapy
• •Patients who have received local therapy except chemoembolization, such as surgery, radiation therapy, hepatic arterial embolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of 25% in the size. Local therapy must be completed at least 4 weeks prior to the baseline scan
• •Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2